Vivo Bio Tech Limited

BSE: 511509 NSE: VIVOBIOT
Vivo Bio Tech Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L65993TG1987PLC007163 Incorporated 12 February 1987 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: VIVOBIOT · BSE: 511509 Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹32.62 Cr
VIVOBIOT · NSE
Share Price
₹12.93
-12.04% today
Revenue
₹53.33 Cr
FY 2025-26 · +14.3% YoY
EBITDA
₹20.84 Cr
Margin 39.1%
Net Profit
−₹1.72 Cr
FY 2025-26 · -145.6% YoY
Authorised capital
₹30 Cr
Registered with MCA
Paid-up capital
₹22.19 Cr
Issued & subscribed
Open charges
₹165.24 Cr
Satisfied ₹90.8 Cr

About Vivo Bio Tech Limited

Data last updated:

Vivo Bio Tech Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 12 February 1987 and has been in existence for over 39 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L65993TG1987PLC007163. Its GSTIN is 36AACCS8320E1ZK (Telangana). The company holds 3 GST registrations, of which 2 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 511509 and NSE: VIVOBIOT.

The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹22.19 Cr. It is led by directors including Sri Kalyan Kompella (Whole-Time Director) and Sankaranarayanan Alangudi (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 03rd Floor Ilyas Mohammed Khan Estate #8 – 2 – 672/5 & 6 Road No.1 Banjara Hills, Hyderabad, Telangana, India – 500034.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹53.33 Cr, a growth of 14.3% compared to the previous year. For the same year it recorded a net loss of ₹1.72 Cr (net margin -3.2%) and EBITDA of ₹20.84 Cr (EBITDA margin 39.1%). The net worth stands at ₹93.16 Cr (up 19.6% YoY). Total assets are valued at ₹161.49 Cr (up 21.7% YoY).

The company has about 5 employees on its provident fund (EPFO) records. Its group structure includes 4 subsidiaries.

The company is associated with 1 brand: Vivo Bio Tech. As per MCA filings, the company has open charges of ₹165.24 Cr and satisfied charges of ₹90.8 Cr on record. Court records list 15 cases involving the company, including 4 filed by the company and 11 filed against it; 1 case is pending. The company has 16 deals on record (16 market trades); the latest was in June 2026.

Vivo Bio Tech Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0001461). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vivobio.com.

Company details

CIN L65993TG1987PLC007163
Registration Number 007163
Incorporation Date 12 February 1987
ROC Hyderabad
Listing Status Listed - Listed on NSE (VIVOBIOT); Listed on BSE (511509)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-02-0001461

CIN history

Vivo Bio Tech has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L65993TG1987PLC007163, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L65993TG1987PLC007163Current
L65993AP1987PLC007163Previous
U65993TG1987PLC007163Previous
Key People
Sri Kalyan Kompella Whole-Time Director Sankaranarayanan Alangudi Whole-Time Director Kalyan Ram Mangipudi Whole-Time Director

Recognitions & Rankings of Vivo Bio Tech

MSME (Udyam registered) Ministry of MSME
Category
Medium (2022-23)
Udyam number
UDYAM-TS-02-0001461

Contact details

Vivo Bio Tech Limited's registered office is in Hyderabad, Telangana. Its website is vivobio.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    vivobio.com
  • Social Media
  • Registered Address
    03rd Floor Ilyas Mohammed Khan Estate #8 – 2 – 672/5 & 6 Road No.1 Banjara Hills, Hyderabad, Telangana, India – 500034
  • Industry
    Pharma, Pharma Contract R&D

To see the full contact details of Vivo Bio Tech Limited, buy the company report.

Comprehensive company report
Vivo Bio Tech Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Vivo Bio Tech operates one associated brand: Vivo Bio Tech. Each brand links to its own profile.

BrandDescriptionWebsite
Vivo Bio Tech
CRO providing drug development, discovery and biologic research servicesvivobio.com

Business activity

The main business activity of Vivo Bio Tech is professional, scientific and technical. In detail, this covers scientific research and development.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
MProfessional, Scientific and TechnicalM5Scientific research and development

To see the full business activity and turnover split of Vivo Bio Tech Limited, buy the company report.

Financials of Vivo Bio Tech Limited

FY 2025-26 filings available

Vivo Bio Tech Limited reported revenue of ₹53.33 Cr (up 14.3% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹53.33 Cr
+14.3% YoY
EBITDA
₹20.84 Cr
+1.3% YoY
Profit After Tax
−₹1.72 Cr
-145.6% YoY
Net Worth
₹93.16 Cr
+19.6% YoY
Total Assets
₹161 Cr
+21.7% YoY
Total Debt
₹67.38 Cr
+24.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue53.3346.6745.4552.2351.3951.7855.35
Revenue growth+14.3%+2.7%-13.0%+1.6%-0.8%-6.5%-
EBITDA20.8420.5721.2621.8416.0817.8112.46
EBITDA margin+39.1%+44.1%+46.8%+41.8%+31.3%+34.4%+22.5%
Profit before tax4.808.804.064.624.468.634.24
Net profit(1.72)3.772.522.652.195.694.43
Net profit margin-3.2%+8.1%+5.5%+5.1%+4.3%+11.0%+8.0%
EPS (₹)(0.82)4.241.701.781.544.233.45
Balance sheet
Total assets16113312811511573.9657.80
Net worth93.1677.9054.4051.8747.1342.5333.03
Total debt67.3854.0273.0662.3967.4430.9624.37
Cash & bank1.441.281.391.371.711.171.03
Net working capital18.9633.1840.5926.1120.2021.5621.04
Cash flow
Cash from operations34.9311.8315.5214.8316.6414.188.61
Cash from investing(59.35)(15.84)(7.95)(4.00)(51.11)(22.82)(10.23)
Cash from financing24.573.90(7.56)(11.18)35.028.782.09
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue14.2814.2013.5113.1112.5112.2912.2112.04
Revenue growth (YoY)+14.2%+15.5%+10.7%+8.9%+23.5%---
Other income0.060.030.140.130.140.150.014.63
EBITDA5.054.455.495.415.495.015.545.60
EBITDA margin+35.4%+31.3%+40.6%+41.3%+43.9%+40.8%+45.4%+46.5%
Depreciation3.532.752.662.572.642.252.252.29
Interest1.241.481.401.471.501.681.842.06
Profit before tax0.340.251.571.501.491.231.465.88
Tax0.155.410.320.640.140.180.640.63
Net profit0.19(5.16)1.250.861.351.050.825.25
EPS (₹)0.08(2.52)0.560.450.740.690.553.51
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue52.5746.6744.8851.6251.3951.7855.35
Revenue growth+12.6%+4.0%-13.1%+0.5%-0.8%-6.5%-
EBITDA20.6220.8521.2621.8216.0817.8012.46
EBITDA margin+39.2%+44.7%+47.4%+42.3%+31.3%+34.4%+22.5%
Profit before tax4.589.084.064.604.468.624.24
Net profit(1.94)4.012.522.632.195.684.43
Net profit margin-3.7%+8.6%+5.6%+5.1%+4.3%+11.0%+8.0%
EPS (₹)(0.93)4.411.691.771.544.243.45
Balance sheet
Total assets15813112611311371.7555.54
Net worth93.2278.1854.3951.8747.1442.5533.04
Total debt63.9251.8070.8360.1765.2428.7322.09
Cash & bank1.301.211.320.991.471.100.99
Net working capital18.8634.5641.6827.2121.3522.6822.11
Cash flow
Cash from operations36.1111.8315.8314.7316.4314.107.72
Cash from investing(59.35)(15.84)(7.95)(4.00)(51.11)(22.82)(7.08)
Cash from financing23.343.90(7.56)(11.20)35.048.83(0.18)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue14.1413.7713.3713.0212.4212.2912.2112.04
Revenue growth (YoY)+13.9%+12.0%+9.5%+8.1%+22.6%---
Other income0.060.030.140.130.140.150.014.63
Total expenses9.099.597.867.606.897.156.606.36
EBITDA5.054.185.515.425.535.145.615.68
EBITDA margin+35.7%+30.4%+41.2%+41.6%+44.5%+41.8%+45.9%+47.2%
Depreciation3.532.752.662.572.642.252.252.29
Interest1.241.481.401.471.501.681.842.06
Profit before tax0.34(0.02)1.591.511.531.361.535.96
Tax0.155.410.320.640.140.180.640.63

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue14.2814.2013.5113.1112.5112.2912.2112.04
Revenue growth (YoY)+14.2%+15.5%+10.7%+8.9%+23.5%---
Other income0.060.030.140.130.140.150.014.63
EBITDA5.054.455.495.415.495.015.545.60
EBITDA margin+35.4%+31.3%+40.6%+41.3%+43.9%+40.8%+45.4%+46.5%
Depreciation3.532.752.662.572.642.252.252.29
Interest1.241.481.401.471.501.681.842.06
Profit before tax0.340.251.571.501.491.231.465.88
Tax0.155.410.320.640.140.180.640.63
Net profit0.19(5.16)1.250.861.351.050.825.25
EPS (₹)0.08(2.52)0.560.450.740.690.553.51
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue53.3346.6745.4552.2351.3951.7855.35
Revenue growth+14.3%+2.7%-13.0%+1.6%-0.8%-6.5%-
Other income0.444.800.040.040.100.080.05
Total expenses32.4926.1024.1930.3935.3133.9742.89
Employee cost0.0012.1410.6813.529.428.5710.00
EBITDA20.8420.5721.2621.8416.0817.8112.46
EBITDA margin+39.1%+44.1%+46.8%+41.8%+31.3%+34.4%+22.5%
Depreciation10.639.029.299.277.455.595.17
Interest5.857.557.957.994.273.673.10
Profit before tax4.808.804.064.624.468.634.24
Tax6.521.511.541.972.272.94(0.19)
Net profit(1.72)3.772.522.652.195.694.43
Net profit margin-3.2%+8.1%+5.5%+5.1%+4.3%+11.0%+8.0%
EPS (₹)(0.82)4.241.701.781.544.233.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital22.1917.1614.9014.9014.2613.4212.89
Reserves & surplus69.3553.4739.5036.9732.1827.6820.14
Shareholders' funds (net worth)93.1677.9054.4051.8747.1342.5333.03
Minority interest0.000.000.000.000.000.000.00
Secured loans55.6451.7367.6459.6362.5028.7320.14
Unsecured loans11.742.295.422.764.942.234.23
Total debt67.3854.0273.0662.3967.4430.9624.37
Total liabilities16113312811511573.9657.80
Assets
Gross block20415914214113988.0165.36
Net block12388.2480.3788.8795.1752.0534.99
Capital work in progress4.8112.849.211.900.870.320.15
Investments21.910.000.000.000.000.000.00
Inventories8.157.798.777.979.8113.2810.58
Sundry debtors11.7511.2511.8012.3812.027.2910.48
Cash & bank balances1.441.281.391.371.711.171.03
Loans & advances7.0821.6125.2810.062.485.354.83
Total current assets28.4241.9347.2431.7826.0227.0926.92
Total current liabilities9.468.756.655.675.825.535.88
Net working capital18.9633.1840.5926.1120.2021.5621.04
Total assets16113312811511573.9657.80
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.281.391.371.711.171.030.56
Net cash from operating activities34.9311.8315.5214.8316.6414.188.61
Net cash from investing activities(59.35)(15.84)(7.95)(4.00)(51.11)(22.82)(10.23)
Net cash from financing activities24.573.90(7.56)(11.18)35.028.782.09
Net change in cash0.15(0.11)0.01(0.34)0.550.140.47
Closing cash1.441.281.391.371.711.171.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.3%+2.7%-13.0%+1.6%-0.8%-6.5%-
EBITDA growth+1.3%-3.3%-2.7%+35.8%-9.7%+42.9%-
PBT growth-45.5%+116.8%-12.1%+3.6%-48.3%+103.5%+133.0%
Net income growth-145.6%+49.6%-4.9%+21.0%-61.5%+28.4%-
Revenue CAGR (3Y)+0.7%-3.2%-4.3%-1.9%-2.7%+3.3%+17.5%
EBITDA CAGR (3Y)-1.6%+8.6%+6.1%+20.6%+19.1%+17.9%+17.7%
Profitability & leverage
Net income margin-3.2%+15.6%+5.5%+5.1%+4.3%+11.0%+8.0%
Return on capital employed-+9.0%+9.9%+11.0%+9.3%+18.7%+13.7%
Return on net worth-+5.7%+4.8%+5.4%+4.9%+15.0%+14.7%
Debt / equity-0.961.271.311.100.730.76
Long-term debt / equity-0.670.860.940.720.320.31
Interest cover57.3065.3766.4263.5649.4830.0342.52
Efficiency & per share
Fixed asset turnover-0.310.320.370.450.680.92
Inventory turnover-5.645.435.884.454.345.88
Debtors turnover-4.053.764.285.325.835.86
EPS (₹)(0.82)4.241.701.781.544.233.45
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0041.1536.5034.8132.5630.6325.62
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue14.1413.7713.3713.0212.4212.2912.2112.04
Revenue growth (YoY)+13.9%+12.0%+9.5%+8.1%+22.6%---
Other income0.060.030.140.130.140.150.014.63
Total expenses9.099.597.867.606.897.156.606.36
EBITDA5.054.185.515.425.535.145.615.68
EBITDA margin+35.7%+30.4%+41.2%+41.6%+44.5%+41.8%+45.9%+47.2%
Depreciation3.532.752.662.572.642.252.252.29
Interest1.241.481.401.471.501.681.842.06
Profit before tax0.34(0.02)1.591.511.531.361.535.96
Tax0.155.410.320.640.140.180.640.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue52.5746.6744.8851.6251.3951.7855.35
Revenue growth+12.6%+4.0%-13.1%+0.5%-0.8%-6.5%-
Other income0.444.800.040.040.090.080.05
Total expenses31.9525.8223.6229.8035.3133.9842.89
Employee cost0.0011.8610.1313.159.428.5710.00
EBITDA20.6220.8521.2621.8216.0817.8012.46
EBITDA margin+39.2%+44.7%+47.4%+42.3%+31.3%+34.4%+22.5%
Depreciation10.639.029.299.277.445.595.17
Interest5.857.557.957.994.273.673.10
Profit before tax4.589.084.064.604.468.624.24
Tax6.521.511.541.972.272.94(0.19)
Net profit(1.94)4.012.522.632.195.684.43
Net profit margin-3.7%+8.6%+5.6%+5.1%+4.3%+11.0%+8.0%
EPS (₹)(0.93)4.411.691.771.544.243.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital22.1917.1614.9014.9014.2613.4212.89
Reserves & surplus69.4153.7539.4936.9732.1927.7020.15
Shareholders' funds (net worth)93.2278.1854.3951.8747.1442.5533.04
Secured loans65.7059.4767.6459.6362.5028.7320.14
Unsecured loans(1.78)(7.67)3.190.542.740.001.95
Total debt63.9251.8070.8360.1765.2428.7322.09
Total liabilities15813112611311371.7555.54
Assets
Gross block20115613913813584.6562.00
Net block12084.8877.0185.5191.8148.6931.63
Capital work in progress4.8112.849.211.900.870.320.15
Investments21.950.040.040.040.040.040.04
Inventories8.157.798.777.979.8113.2810.58
Sundry debtors11.7511.2111.3712.3812.027.2910.48
Cash & bank balances1.301.211.320.991.471.100.99
Loans & advances6.9623.1026.7611.543.876.545.94
Total current assets28.1643.3148.2232.8827.1728.2127.99
Total current liabilities9.308.756.545.675.825.535.88
Net working capital18.8634.5641.6827.2121.3522.6822.11
Total assets15813112611311371.7555.54
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.211.320.991.471.100.990.53
Net cash from operating activities36.1111.8315.8314.7316.4314.107.72
Net cash from investing activities(59.35)(15.84)(7.95)(4.00)(51.11)(22.82)(7.08)
Net cash from financing activities23.343.90(7.56)(11.20)35.048.83(0.18)
Net change in cash0.09(0.11)0.32(0.47)0.370.110.46
Closing cash1.301.211.320.991.471.100.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.6%+4.0%-13.1%+0.5%-0.8%-6.5%-
EBITDA growth-1.1%-1.9%-2.6%+35.7%-9.7%+42.9%-
PBT growth-49.6%+123.7%-11.7%+3.1%-48.3%+103.3%+133.0%
Net income growth-148.4%+59.1%-4.2%+20.1%-61.4%+28.2%-
Revenue CAGR (3Y)+0.6%-3.2%-4.7%-2.3%-2.7%+3.3%+17.5%
EBITDA CAGR (3Y)-1.9%+9.1%+6.1%+20.5%+19.1%+17.9%+17.7%
Profitability & leverage
Net income margin-3.7%+16.2%+5.6%+5.1%+4.3%+11.0%+8.0%
Return on capital employed-+9.4%+10.1%+11.2%+9.5%+19.3%+14.0%
Return on net worth-+6.1%+4.7%+5.3%+4.9%+15.0%+14.7%
Debt / equity-0.931.231.271.050.670.73
Long-term debt / equity-0.550.760.900.670.260.27
Interest cover58.5663.8266.4263.6749.4230.0642.52
Efficiency & per share
Fixed asset turnover-0.320.320.380.470.710.95
Inventory turnover-5.645.365.814.454.345.88
Debtors turnover-4.133.784.235.325.835.86
EPS (₹)(0.93)4.411.691.771.544.243.45
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0041.3236.5034.8132.5730.6425.63

To see the full year-wise statements and ratios of Vivo Bio Tech Limited, buy the company report.

Board of directors of Vivo Bio Tech Limited

Vivo Bio Tech has 6 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sri Kalyan Kompella
Also directs: Pragnapur Developers Private Limited, Shri Shri Resorts Private Limited, Gajwel Developers Private Limited and 5 more
Whole-Time Director03 Nov 20214 Years 11 MonthsCurrent
Sankaranarayanan Alangudi
Also directs: Vivobio Discovery Services Private Limited, Vivobio Labs Private Limited, Surlogic Life Consultancy Private Limited and 2 more
Whole-Time Director27 May 201610 Years 4 MonthsCurrent
Kalyan Ram Mangipudi
Also directs: Vivobio Discovery Services Private Limited, Bharat Megawatts Gen Private Limited, Pragnapur Developers Private Limited and 5 more
Whole-Time Director26 Nov 200916 Years 10 MonthsCurrent
Priya Rajender Goda
Also directs: Virinchi Limited
Director11 Jun 20251 Years 4 MonthsCurrent
Satyanarayana Vedula
Also directs: Virinchi Limited, Tyohar Foods Private Limited, V23 Medical Solutions Private Limited and 4 more
Director11 Jun 20251 Years 4 MonthsCurrent
Shyam Sunder Tipparaju
Also directs: Vivobio Discovery Services Private Limited, Vivobio Labs Private Limited, Surlogic Life Consultancy Private Limited and 5 more
Director31 Aug 20233 Years 1 MonthsCurrent
View all directors

Auditor

Vivo Bio Tech Limited is audited by PCN & ASSOCIATES for the financial year 2022.

Auditor firmFinancial yearFirm registration number
PCN & ASSOCIATESFY 2022016016S

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 30.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 69.40%.

Promoters: 30.60%Retail & Others: 69.40%
Sep 2026
QUARTER
30.60% Promoters
69.40% Retail & Others
Promoter holding - history
Now 30.60% · Sep 2026High 35.40% · Jun 2026Low 30.60% · Sep 2026
29%31%33%35%37%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 35.20%Mar 2026: 35.20%Jun 2026: 35.40%Sep 2026: 30.60%35.40%30.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters30.60%35.40%35.20%35.20%
Public69.40%64.60%64.80%64.80%

Charges & borrowings

Open charges
₹165.24 Cr
Satisfied charges
₹90.8 Cr
Breakdown by lending institutions
Canara Bank₹133.44 Cr
Others₹19.55 Cr
The South Indian Bank Limited₹6.45 Cr
Department of Biotechnology₹5.70 Cr
Bank of Baroda₹0.10 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
02 Jul 2026101321205The South Indian Bank Limited₹77.9 LakhOpen
23 Jun 2026101321210The South Indian Bank Limited₹35.25 LakhOpen
26 Nov 2025101209687Others₹7.57 CrOpen
25 Sep 2025101165362The South Indian Bank Limited₹52 LakhOpen
25 Sep 2025101193981Others₹3.65 CrOpen

To see the full charge records of Vivo Bio Tech Limited, buy the company report.

Total charge records: 30 View all charges

Deals & funding

Vivo Bio Tech Limited has 16 deals on record (16 market trades); the latest was in June 2026.

Total deals
16
Market trades
16

Deals on record (5 of 16)

WhenDealAmountParties
Jun 2026Market trade₹2.42 CrBuyer: More Agrisupplies & Services Private Limited , Vean Smart Infra Private Limited
Seller: Shri Shri Resorts Private Limited
Jan 2025Market trade₹98.8 LakhSeller: Every Wear Import and Export Private Limited
Dec 2024Market trade₹30.5 LakhSeller: Vean Smart Infra Private Limited
Nov 2024Market trade₹29.2 LakhSeller: Vean Smart Infra Private Limited
Apr 2022Market trade₹33.2 LakhSeller: More Agrisupplies & Services Private Limited

To see the full deal history of Vivo Bio Tech Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Vivo Bio Tech Limited was last rated by Brickwork on 23 May 2022.

Rating agencyRated onRating
Brickwork23 May 2022

To see the full credit ratings and regulatory alerts of Vivo Bio Tech Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Vivo Bio Tech Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Vivo Bio Tech has 4 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

4
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Vivobio Discovery Services Private LimitedU24232TG2009PTC065604
Vivobio Labs Private LimitedU73100TG2009PTC065603
Surlogic Life Consultancy Private LimitedU74999TG2010PTC068943
Vivobio Consulting Services Private LimitedU74999TG2018PTC125356

To see the full group structure of Vivo Bio Tech Limited, buy the company report.

Employees & EPFO

Vivo Bio Tech Limited has a workforce of 5 employees on its EPFO records as of Apr 06, 2024, across 2 active EPFO establishments.

Employee count
5
Active EPFO establishments
2
Employee growth
-94.9%

GST

Vivo Bio Tech has 3 GST registrations: 2 active and 1 cancelled or inactive.

Total GSTINs
3
Active
2
Cancelled / inactive
1
GSTINStateStatusRegistered on
36AACCS8320E1ZKTelanganaActive01 Jul 2017
37AACCS8320E2ZHAndhra PradeshActive31 Mar 2022

To see the full GST registrations and return filing status of Vivo Bio Tech Limited, buy the company report.

Recent activity

Vivo Bio Tech Limited has 38 board changes on record since 2005: 22 appointments and 16 cessations. The latest: Kunda Kalpana ceased to be Director on 29 Jun 2025.

Charges
A charge with The South Indian Bank Limited amounted to Rs. 0.78 Cr with Charge ID 101321205 was registered on 02 Jul 2026.
Charges
A charge with The South Indian Bank Limited amounted to Rs. 0.35 Cr with Charge ID 101321210 was registered on 23 Jun 2026.
Charges
A charge registered on 17 Oct 2023 via Charge ID 100854356 with Others was fully satisfied on 15 Jun 2026.
Charges
A charge registered on 17 Oct 2023 via Charge ID 100854358 with Others was fully satisfied on 15 Jun 2026.
Filing
Vivo Bio Tech Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
A charge with Canara Bank of Rs. 64.39 Cr registered on 14 Oct 2016 with Charge ID 100075099 was modified on 19 Feb 2026.
Charges
A charge with Others amounted to Rs. 7.57 Cr with Charge ID 101209687 was registered on 26 Nov 2025.
Charges
A charge registered on 01 Jun 2018 via Charge ID 100211811 with Canara Bank was fully satisfied on 29 Oct 2025.
Charges
A charge registered on 27 Jul 2012 via Charge ID 10376839 with Canara Bank Ltd was fully satisfied on 29 Oct 2025.
Charges
A charge registered on 17 Oct 2023 via Charge ID 100854570 with Others was fully satisfied on 28 Oct 2025.
AGM
Vivo Bio Tech Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge with The South Indian Bank Limited amounted to Rs. 0.52 Cr with Charge ID 101165362 was registered on 25 Sep 2025.

79 earlier events are in the company report.

News

Vivo Bio Tech to announce Quarterly Result
02 Feb 2025 · India Infoline

Frequently asked questions

Vivo Bio Tech is an active public limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 12 February 1987 (39+ years old) and is registered under CIN L65993TG1987PLC007163. Listed on BSE: 511509 and NSE: VIVOBIOT.

Vivo Bio Tech reported revenue of ₹53.33 Cr for FY 2025-26 (up 14.3% YoY) based on consolidated financials.

Vivo Bio Tech has 6 current directors:

The latest financial statements of Vivo Bio Tech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Vivo Bio Tech is 36AACCS8320E1ZK, registered in Telangana. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 37AACCS8320E2ZH (Andhra Pradesh).

The CIN (Corporate Identification Number) of Vivo Bio Tech is L65993TG1987PLC007163. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Vivo Bio Tech is a listed company as per MCA records. Its shares are listed on both BSE (code: 511509) and NSE (symbol: VIVOBIOT).

Vivo Bio Tech has 15 court cases on record: 4 filed by the company and 11 filed against it. 1 is pending. Most are in the high courts.

Vivo Bio Tech was incorporated on 12 February 1987, making it 39+ years old. It is registered with the Registrar of Companies, Hyderabad.

Vivo Bio Tech has 16 deals on record (16 market trades); the latest was in June 2026.